Overview

Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia

Status:
Active, not recruiting

Trial end date:
2023-02-15

Target enrollment:

Participant gender:

Summary

This study is designed to confirm the efficacy, safety, and tolerability of blinatumomab in patients with MRD of B- precursor ALL in complete hematological remission including patients with relapse after SCT. The study aims to expand experience generated in previous trials in patients with MRD positive ALL with a focus on additional specific questions.

Phase:

Phase 2

Details

Lead Sponsor:

Goethe University
Johann Wolfgang Goethe University Hospital

Treatments:

Antibodies, Bispecific
Blinatumomab